Checkpoint Therapeutics, Inc.: Nasdaq/NYSE listing notice — Checkpoint Therapeutics fails Nasdaq board independence rule after director resignation

Checkpoint Therapeutics, Inc.

Scott Boilen resigned from Board effective Jan 31, 2024; company no longer has majority independent directors as required by Nasdaq Rule 5605(b)(1).
Nasdaq confirmed non-compliance via letter on Feb 2, 2024; no immediate impact on listing or trading of CKPT common stock.
Company has cure period until earlier of next annual shareholders' meeting or Jan 31, 2025; if annual meeting before July 29, 2024, compliance due July 29, 2024.
Board intends to regain compliance with Board Independence Rule before cure period expires.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.97

Checkpoint Therapeutics, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: board independence
Rules: 5605(b)(1), 5605(a)(2)

Exact text from the filing

February 2, 2024, the Company received a letter from Nasdaq confirming that the Company was no longer in compliance with the Board Independence Rule. The Company’s non-compliance with the Board Independence Rule does not have an immediate effect on the listing or trading of the Company’s common stock, which continues to be listed and traded on the Nasdaq Capital Market under the symbol “CKPT.” In accordance with Rule 5605(b)(1)(A) of the Nasdaq listing standards, the Company has until the earlier of its next annual shareholders’ meeting or January 31, 2025, to regain compliance; provided, howe

View on SEC.gov

Browse all listing & compliance notices →

Source: SEC EDGAR

accession 0001104659-24-010161

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.